Literature DB >> 16982687

Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function.

Stéphane Pelletier1, Sébastien Gingras, Megumi Funakoshi-Tago, Sherié Howell, James N Ihle.   

Abstract

Biochemical and genetic studies have shown that Jak2 is an essential component of EpoR signal transduction which is required for normal erythropoiesis. However, whether Jak2 is the sole direct mediator of EpoR signal transduction remains controversial. To address this issue, we have used an extensive and systematic mutational analysis across the EpoR cytoplasmic tail and transmembrane domain with the goal of determining whether mutants that negatively affected EpoR biological activity but retained Jak2 activation could be identified. Analysis of over 40 mutant receptors established that two large domains in the membrane-proximal region, which include the previously defined Box1 and Box2 domains as well as a highly conserved glycine among cytokine receptors, are required for Jak2 binding and activation and to sustain biological activity of the receptor. Importantly, none of the mutants that lost the ability to activate Jak2 retained the ability to bind Jak2, thus questioning the validity of models of receptor reorientation for Jak2 activation. Also, no correlation was made between cell surface expression of the receptor and its ability to bind Jak2, thus questioning the role of Jak2 in trafficking the receptor to the plasma membrane. Collectively, the results suggest that Jak2 is the sole direct signaling molecule downstream of EpoR required for biological activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982687      PMCID: PMC1636781          DOI: 10.1128/MCB.01035-06

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  17 in total

1.  Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domains.

Authors:  Xiaohui Lu; Alec W Gross; Harvey F Lodish
Journal:  J Biol Chem       Date:  2006-01-12       Impact factor: 5.157

2.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

Authors:  S N Constantinescu; L J Huang; H Nam; H F Lodish
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

3.  Dimer- and oligomerization of the erythropoietin receptor by disulfide bond formation and significance of the region near the WSXWS motif in intracellular transport.

Authors:  O Miura; J N Ihle
Journal:  Arch Biochem Biophys       Date:  1993-10       Impact factor: 4.013

Review 4.  Quality control of receptor-kinase signaling complexes.

Authors:  Juan S Bonifacino
Journal:  Dev Cell       Date:  2002-01       Impact factor: 12.270

5.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

Authors:  L J Huang; S N Constantinescu; H F Lodish
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

6.  Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor.

Authors:  Y Miura; O Miura; J N Ihle; N Aoki
Journal:  J Biol Chem       Date:  1994-11-25       Impact factor: 5.157

7.  Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited.

Authors:  Sigrun R Hofmann; Albert Q Lam; Stephan Frank; Yong-Jie Zhou; Haydeé L Ramos; Yuka Kanno; Davide Agnello; Richard J Youle; John J O'Shea
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

8.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.

Authors:  Nadine Seubert; Yohan Royer; Judith Staerk; Katharina F Kubatzky; Virginie Moucadel; Shyam Krishnakumar; Steven O Smith; Stefan N Constantinescu
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

9.  JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin.

Authors:  B A Witthuhn; F W Quelle; O Silvennoinen; T Yi; B Tang; O Miura; J N Ihle
Journal:  Cell       Date:  1993-07-30       Impact factor: 41.582

10.  Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling.

Authors:  Kai He; Xiangdong Wang; Jing Jiang; Ran Guan; Kenneth E Bernstein; Peter P Sayeski; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2003-08-14
View more
  26 in total

1.  Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.

Authors:  Diederik van Bodegom; Jun Zhong; Nadja Kopp; Chaitali Dutta; Min-Sik Kim; Liat Bird; Oliver Weigert; Jeffrey Tyner; Akhilesh Pandey; Akinori Yoda; David M Weinstock
Journal:  Blood       Date:  2012-08-20       Impact factor: 22.113

2.  Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses.

Authors:  Leila N Varghese; Daniela Ungureanu; Nicholas P D Liau; Samuel N Young; Artem Laktyushin; Henrik Hammaren; Isabelle S Lucet; Nicos A Nicola; Olli Silvennoinen; Jeffrey J Babon; James M Murphy
Journal:  Biochem J       Date:  2014-03-01       Impact factor: 3.857

3.  Three lysine residues in the common β chain of the interleukin-5 receptor are required for Janus kinase (JAK)-dependent receptor ubiquitination, endocytosis, and signaling.

Authors:  Jonathan T Lei; Tuhina Mazumdar; Margarita Martinez-Moczygemba
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

4.  Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance.

Authors:  Yiting Cao; Justin D Lathia; Christine E Eyler; Qiulian Wu; Zhizhong Li; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Genes Cancer       Date:  2010-01-01

5.  EPO receptor circuits for primary erythroblast survival.

Authors:  Pradeep Sathyanarayana; Arvind Dev; Jing Fang; Estelle Houde; Olga Bogacheva; Oleg Bogachev; Madhu Menon; Sarah Browne; Anamika Pradeep; Christine Emerson; Don M Wojchowski
Journal:  Blood       Date:  2008-03-18       Impact factor: 22.113

6.  EPO receptor gain-of-function causes hereditary polycythemia, alters CD34 cell differentiation and increases circulating endothelial precursors.

Authors:  Silverio Perrotta; Valeria Cucciolla; Marcella Ferraro; Luisa Ronzoni; Annunziata Tramontano; Francesca Rossi; Anna Chiara Scudieri; Adriana Borriello; Domenico Roberti; Bruno Nobili; Maria Domenica Cappellini; Adriana Oliva; Giovanni Amendola; Anna Rita Migliaccio; Patrizia Mancuso; Ines Martin-Padura; Francesco Bertolini; Donghoon Yoon; Josef T Prchal; Fulvio Della Ragione
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

7.  Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity.

Authors:  Megumi Funakoshi-Tago; Stéphane Pelletier; Hiroshi Moritake; Evan Parganas; James N Ihle
Journal:  Mol Cell Biol       Date:  2007-12-26       Impact factor: 4.272

8.  The Structural Basis for Class II Cytokine Receptor Recognition by JAK1.

Authors:  Ryan Ferrao; Heidi J A Wallweber; Hoangdung Ho; Christine Tam; Yvonne Franke; John Quinn; Patrick J Lupardus
Journal:  Structure       Date:  2016-04-28       Impact factor: 5.006

9.  Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

Authors:  Florian Grebien; Marc A Kerenyi; Boris Kovacic; Thomas Kolbe; Verena Becker; Helmut Dolznig; Klaus Pfeffer; Ursula Klingmüller; Mathias Müller; Hartmut Beug; Ernst W Müllner; Richard Moriggl
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

10.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Authors:  Gerlinde Wernig; Jeffrey R Gonneville; Brian J Crowley; Margret S Rodrigues; Mamatha M Reddy; Heidi E Hudon; Christoph Walz; Andreas Reiter; Klaus Podar; Yohan Royer; Stefan N Constantinescu; Michael H Tomasson; James D Griffin; D Gary Gilliland; Martin Sattler
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.